Frontlight ResearchEarly access
Immune thrombocytopenia (ITP) trials in China
65 of 69 trials · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleAnti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
- Where
- Tianjin
- Age
- 18 years and over
- People
- 20
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07362199 - Phase 2Taking peopleDaratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)
- Where
- Tianjin
- Age
- 6 years to 18 years
- People
- 122
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07362238 - Phase 2Taking peopleA Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)
- Where
- Jinan
- Age
- 18 years and over
- People
- 60
- Run by
- Dizal Pharmaceuticals
See details and how to joinNCT07294365 - Phase 1Taking peopleCAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
- Where
- Tianjin
- Age
- 18 years and over
- People
- 12
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07315087 - No phaseNot yet taking people in ChinaA Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases
- Where
- Tianjin
- Age
- 18 years to 65 years
- People
- 24
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07212322 - Phase 1/2Taking peopleA Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia
- Where
- Changzhi, Tianjin, Zhengzhou
- Age
- 18 years and over
- People
- 158
- Run by
- Keymed Biosciences Co.Ltd
See details and how to joinNCT07175493 - No phaseTaking peopleEfficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia
- Where
- Suzhou
- Age
- 14 years and over
- People
- 30
- Run by
- The First Affiliated Hospital of Soochow University
See details and how to joinNCT07206823 - Phase 2Taking peopleAnti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)
- Where
- Tianjin
- Age
- 6 years to 17 years
- People
- 60
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06168851 - Early phase 1Not yet taking people in ChinaSafety and Efficacy of PRG-1801 in Recurrent/Refractory Primary Immune Thrombocytopenia (ITP)
- Where
- Wuhan
- Age
- 18 years and over
- People
- 6
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT06519565 - Phase 1Taking peopleCAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
- Where
- Tianjin
- Age
- 18 years and over
- People
- 12
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06941129 - Phase 1/2Not yet taking people in ChinaAn Exploratory Study of Golidocitinib in Adult Patients With ITP
- Where
- Beijing
- Age
- 18 years to 80 years
- People
- 138
- Run by
- Peking University People's Hospital
See details and how to joinNCT07196163 - Phase 4Not yet taking people in ChinaSequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP
- Where
- Wuhan
- Age
- 12 years to 75 years
- People
- 150
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07189910 - Early phase 1Taking peopleSafety Study of CC312 in Autoimmune Disease Patients
- Where
- Tianjin
- Age
- 18 years and over
- People
- 18
- Run by
- CytoCares Inc
See details and how to joinNCT06888960 - Phase 2Taking peopleThe Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2)
- Where
- Beijing
- Age
- 18 years and over
- People
- 132
- Run by
- Peking University People's Hospital
See details and how to joinNCT07065968 - No phaseTaking peopleAnti CD19/BCMA CAR Gene Therapy for Relapsed/Refractory Immune Thrombocytopenia
- Where
- Changsha
- Age
- 18 years and over
- People
- 18
- Run by
- Anhui Provincial Hospital
See details and how to joinNCT06973356 - Phase 1Taking peopleInaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia
- Where
- Beijing
- Age
- 18 years to 70 years
- People
- 12
- Run by
- Juventas Cell Therapy Ltd.
See details and how to joinNCT06826430 - Phase 1/2Taking peopleA Clinical Study of NAD in the Treatment of Immune Thrombocytopenia
- Where
- Tianjin
- Age
- 18 years and over
- People
- 20
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06776510 - Phase 2Taking peopleAnti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP)
- Where
- Tianjin
- Age
- 6 years to 18 years
- People
- 30
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06838962 - Phase 2Not yet taking people in ChinaA Study on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in Adults
- Where
- Anyang, Baoding, Beijing, Changchun, Changsha, Changzhi, Chengde, Chongqing, Ganzhou, Guangzhou, Guiyang, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Linyi, Nanchang, Nanjing, Nanning, Nantong, Nanyang, Ningbo, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Tangshan, Tianjin, Ürümqi, Wuhan, Wuhu, Xi'an, Xi’an, Xining, Yantai, Zhanjiang, Zhengzhou
- Age
- 18 years and over
- People
- 320
- Run by
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
See details and how to joinNCT07083739 - Phase 2Not yet taking people in ChinaThe Combination of Upadacitinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia
- Where
- Beijing
- Age
- 18 years to 70 years
- People
- 132
- Run by
- Peking University People's Hospital
See details and how to joinNCT07064889 - Phase 2Taking peopleAnti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP)
- Where
- Tianjin
- Age
- 60 years and over
- People
- 30
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07063199 - Phase 2Not yet taking people in ChinaIguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITP
- Where
- Beijing
- Age
- 18 years to 70 years
- People
- 120
- Run by
- Peking University People's Hospital
See details and how to joinNCT07057778 - Phase 1/2Taking peopleA Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia
- Where
- Jinan, Kunming, Nanchang, Tangshan, Tianjin, Zhengzhou
- Age
- 18 years to 65 years
- People
- 75
- Run by
- CASI pharmaceuticals, Inc.
See details and how to joinNCT07017725 - Phase 2Taking peopleRomiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Interventional Trial
- Where
- Tianjin
- Age
- 18 years to 75 years
- People
- 129
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06992128 - Phase 3Taking peopleA Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia
- Where
- Anyang, Baoding, Beijing, Changchun, Changsha, Changzhi, Chengde, Chongqing, Ganzhou, Guangzhou, Guiyang, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Linyi, Nanchang, Nanjing, Nanning, Nantong, Nanyang, Ningbo, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Tangshan, Tianjin, Ürümqi, Wuhan, Wuhu, Xi'an, Xi’an, Xining, Xuchang, Yangzhou, Yantai, Zhanjiang, Zhengzhou
- Age
- 18 years to 75 years
- People
- 199
- Run by
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
See details and how to joinNCT06900920